Combination chemotherapy with anti-angiogenic monoclonal antibody

This page covers all Combination chemotherapy with anti-angiogenic monoclonal antibody drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting DNA (gemcitabine, cisplatin); VEGF (bevacizumab), Multiple: microtubules (paclitaxel), VEGF (bevacizumab), DNA (doxorubicin), thymidylate synthase (capecitabine).

Targets

DNA (gemcitabine, cisplatin); VEGF (bevacizumab) · Multiple: microtubules (paclitaxel), VEGF (bevacizumab), DNA (doxorubicin), thymidylate synthase (capecitabine)

Marketed (1)

• gemcitabine, cisplatin and bevacizumab · Fundacion Clinic per a la Recerca Biomédica · Oncology
  This combination uses gemcitabine and cisplatin as chemotherapy agents to damage cancer cell DNA, while bevacizumab blocks tumor blood vessel formation to inhibit cancer growth.

Phase 3 pipeline (1)

• Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine · Borstkanker Onderzoek Groep · Oncology
  This combination regimen uses multiple chemotherapy agents and an anti-angiogenic antibody to kill cancer cells through distinct mechanisms: microtubule stabilization, vascular disruption, DNA intercalation, and antimetabolite activity.